Login Register
icon_bulk_orderBulk order Acrobiosystems for English
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > IFN-gamma


Brief Information

Name:Interferon gamma
Target Synonym:Immune interferon,Interferon gamma,IFNG,IFN-Gamma,IFG,IFI,Interferon-gamma
Number of Launched Drugs:4
Number of Drugs in Clinical Trials:8
Lastest Research Phase:Approved

Product ListCompare or Buy

Part of Bioactivity data

IFG-H4211-Cell-based assay
 IFN-gamma CELL

The bio-activity of Human IFN-gamma, premium grade (Cat. No. IFG-H4211) was determined by dose-dependent inhibition of the proliferation of HT-29 cells. The EC50 for this effect is typically 0.41-0.74 ng/mL (Routinely tested).


Biotinylated Monoclonal Anti-IFNγ antibody, Mouse IgG1 (13E6H6) (Cat. No. IFN-BS138) captured on CM5 chip via anti-mouse antibodies surface can bind ActiveMax® Human IFN-gamma, Tag Free (Cat. No. IFG-H4211) with an affinity constant of 1.28 nM as determined in a SPR assay (Biacore 8K) (Routinely tested).


Monoclonal Anti-IFNγ antibody, Mouse IgG2a (8C5F8) (Cat. No. IFN-S120) captured on CM5 chip via anti-mouse antibodies surface can bind ActiveMax® Human IFN-gamma, Tag Free (Cat. No. IFG-H4211) with an affinity constant of 0.933 nM as determined in a SPR assay (Biacore 8K) (QC tested).

Synonym Name

Interferon-gamma ,Interferon-γ


Interferon-gamma (IFN-γ/IFNG) is a dimerized soluble cytokine that is the only member of the type II class of interferon. This interferon was originally called macrophage-activating factor, a term now used to describe a larger family of proteins to which IFN-γ belongs. IFN-gamma has been used in a wide variety of clinical indications. Interferon-gamma (IFNgamma) is a central regulator of the immune response and signals via the Janus Activated Kinase (JAK)-Signal Transducer and Activator of Transcription (STAT) pathway. Interferon gamma has broader roles in activation of innate and adaptive immune responses to viruses and tumors, in part through upregulating transcription of genes involved in cell cycle regulation, apoptosis, and antigen processing/presentation. Despite this, rodent and human trophoblast cells show dampened responses to IFNG that reflect the resistance of these cells to IFNG-mediated activation of major histocompatibility complex (MHC) class II transplantation antigen expression.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Cadi-05 Cadi-05 Approved National Institute Of Allergy And Infectious Diseases (Niaid) Immuvac, Leprovac, Mycidac-C India Carcinoma, Non-Small-Cell Lung; Leprosy null 1998-01-01 Leprosy; Carcinoma, Non-Small-Cell Lung Details
Emapalumab NI-0501 Approved Novimmune Gamifant Mainland China Lymphohistiocytosis, Hemophagocytic Sobi Pharmaceutical (Guangzhou) Co Ltd 2018-11-20 Macrophage Activation Syndrome; Still's Disease, Adult-Onset; Rare Diseases; Immune System Diseases; Arthritis, Juvenile; Lupus Erythematosus, Systemic; Lymphohistiocytosis, Hemophagocytic Details
Thalidomide NSC-66847; NSC-527179; K-17; VP-02 Approved Celgene Corp Talizer, Thalidomide Celgene, Thalidomide Pharmion, Synovir, Thalomid, Thaled Japan Leprosy, Lepromatous Fujimoto Pharmaceutical 1982-01-01 Waldenstrom Macroglobulinemia; Sarcoma; Prostatic Neoplasms; Arachnoiditis; Cholangitis, Sclerosing; Gastrointestinal Hemorrhage; Osteosarcoma; Pancreatitis, Chronic; Retinoblastoma; Sarcoma, Ewing; Lymphoma, Mantle-Cell; Prostatitis; Colitis, Ulcerative; Colorectal Neoplasms; Neuroectodermal Tumors, Primitive; Erythema Nodosum; Leprosy, Lepromatous; Endometrial Neoplasms; Appendiceal Neoplasms; Pelvic Pain; Angiodysplasia; Glioma; Lymphoma, Non-Hodgkin; Carcinoma, Hepatocellular; Amyotrophic Lateral Sclerosis; Vascular Malformations; Crohn Disease; Precancerous Conditions; Mycobacterium avium-intracellulare Infection; Idiopathic Pulmonary Fibrosis; Leukemia; Lymphoma, B-Cell, Marginal Zone; Lymphoma, B-Cell; Liver Neoplasms; Cough; Telangiectasia, Hereditary Hemorrhagic; Mycobacterium Infections; Rhabdomyosarcoma; Arteriovenous Malformations; Inflammatory Bowel Diseases; Stomatitis, Aphthous; Gastric Antral Vascular Ectasia; Spondylitis, Ankylosing; Myelodysplastic Syndromes; HIV Infections; Coronavirus Dise Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
OCH-NCNP1 OCH-NCNP1 Phase 2 Clinical Keio University Multiple Sclerosis; Crohn Disease Details
SP-002 SP-002; ASN-002; TG-1042 Details
PP-001 PP-001; KIO-101 Phase 2 Clinical 4sc Ag Xerophthalmia Details
AMG-811 AMG-811 Amgen Inc Details
AS-1409 AS-1409 Emd Lexigen, Antisoma Details
Recombinant human interferon gamma adenovirus injection Phase 1 Clinical Guangzhou Dabo Biological Products Co Ltd Liver Neoplasms; Nasopharyngeal Neoplasms; Prostatic Neoplasms, Castration-Resistant Details
Vidofludimus 4SC-101; SC-12267 Phase 2 Clinical 4sc Ag Inflammatory Bowel Diseases; Arthritis, Rheumatoid; Colitis, Ulcerative Details
Tadekinig alfa (AB2 Bio) Phase 3 Clinical Ab2 Bio Macrophage Activation Syndrome; Lymphohistiocytosis, Hemophagocytic Details
PDS-0101 PDS-0101B; PDS-0101C; PDS-0101; PDS-0101A; PDS-101 Phase 2 Clinical Pds Biotechnology Corporation, Merck Serono Head and Neck Neoplasms; Papillomavirus Infections; Oropharyngeal Neoplasms Details

This web search service is supported by Google Inc.

Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message